Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.

A drug that has recently been approved for the treatment of schizophrenia could one day be prescribed to Alzheimer’s patients ...

The US FDA has approved Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults.

Since a schizophrenia drug, the first in decades with an innovative mechanism of action, gained US regulatory approval in ...

Vanderbilt University has described muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia, sleep disorders ...

Medically reviewed by Paria Sanaty Zadeh, PharmD Ophthalmic atropine sulfate is a muscarinic antagonist that works to both ...

The drug – a selective muscarinic M4 receptor positive allosteric modulator (PAM) – is designed to have limited effect on dopamine neurotransmission, a mechanism thought to contribute to ...

Despite previous low sentiment towards Neurocrine’s muscarinic program, this competitive failure provides a chance for a larger market opportunity, assuming Neurocrine successfully navigates the ...

The pharmacotherapy of schizophrenia is currently dominated by atypical antipsychotics that primarily target dopaminergic signalling, the dysregulation of which has long been considered to have a ...